Intra-abdominal candidiasis: it's still a long way to get unquestionable data.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Antifungal Use in Perforated Peptic Ulcer Disease: A Western Australian Perspective.Cureus · 2024
   Article
2. Farnesol remodels the peritoneal cavity immune environment influencingInfection and immunity · 2023
   Article
3. Combination of serum and peritoneal 1.3-beta-D-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study.Critical care (London, England) · 2023
   Article
4. Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.Critical care (London, England) · 2023
   Review
5. Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model.Antimicrobial agents and chemotherapy · 2021
   Article
6. Appropriate Source Control and Antifungal Therapy are Associated with Improved Survival in Critically Ill Surgical Patients with Intra-abdominal Candidiasis.World journal of surgery · 2020
   Article
7. Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.Antimicrobial agents and chemotherapy · 2020
   Article
8. Calculated parenteral initial treatment of bacterial infections: Intra-abdominal infections.GMS infectious diseases · 2020
   Article
9. Personalized medicine with IgGAM compared with standard of care for treatment of peritonitis after infectious source control (the PEPPER trial): study protocol for a randomized controlled trial.Trials · 2019
   Article
10. What every intensivist should know about the management of peritonitis in the intensive care unit.Revista Brasileira de terapia intensiva · 2018
    Article
11. [Antibiotic therapy of intra-abdominal infections in the era of multiresistance].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2016
    Review
12. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment.PloS one · 2016
    Article

Corrections and comments

• Comment on
  A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality.2015

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as